# Innovent Biologics

Source: https://onco.cc/companies/innovent/  
OnCo record `innovent` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda.

## Summary

Founded by Michael Yu in Suzhou BioBay; sintilimab (Tyvyt) approved 2018 and now in six indications, four biosimilars (bevacizumab, rituximab, adalimumab, trastuzumab), fulzerasib (with GenFleet), equecabtagene autoleucel (with IASO), and the Claudin 18.2 ADC IBI343. Out-licensing: the DLL3 ADC IBI3009 to Roche (January 2025) and the PD-1/IL-2 alpha-bias bispecific IBI363 plus IBI343 to Takeda (October 2025, $1.2 billion upfront, up to $11.4 billion). Also the GLP-1 mazdutide outside oncology. Lilly co-markets Tyvyt in China.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: 信达生物; Innovent Biologics (Suzhou); Innovent Biopharmaceutical Technology (Hangzhou); Innovent Biologics
- Tags: china
- HQ: Suzhou
- Type: biotech
- Website: https://www.innoventbio.com/
- Ticker: 1801.HK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Innovent_Biologics
- Official website: https://www.innoventbio.com/
- Innovent and Takeda global partnership (October 2025): https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=524

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Equecabtagene autoleucel](https://onco.cc/drugs/equecabtagene-autoleucel/), [Fulzerasib](https://onco.cc/drugs/fulzerasib/), [IBI310](https://onco.cc/drugs/ibi310/), [IBI343](https://onco.cc/drugs/ibi343/), [IBI354](https://onco.cc/drugs/ibi354/), [IBI363](https://onco.cc/drugs/ibi363/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Taletrectinib](https://onco.cc/drugs/taletrectinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/), [GenFleet Therapeutics](https://onco.cc/companies/genfleet/), [IASO Biotherapeutics](https://onco.cc/companies/iaso-bio/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Takeda](https://onco.cc/companies/takeda/)
- trials: [A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05923008/), [A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.](https://onco.cc/trials/nct06982924/), [A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer](https://onco.cc/trials/nct05890742/), [A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors](https://onco.cc/trials/nct05636215/), [A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)](https://onco.cc/trials/g-hope-002/), [A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06083207/), [A Study of IBI363 in Subjects With Advanced Melanoma](https://onco.cc/trials/nct06081920/), [A Study of IBI363 in Subjects with Advanced Solid Malignancies](https://onco.cc/trials/nct06281678/), [A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment](https://onco.cc/trials/nct07490262/), [A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat](https://onco.cc/trials/nct06797297/), [CONTINUUM](https://onco.cc/trials/continuum/), [Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC](https://onco.cc/trials/nct07492342/), [FUMANBA-1](https://onco.cc/trials/fumanba-1/), [IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06974812/), [IBI343 in Combination Therapy for Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07483554/), [IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation](https://onco.cc/trials/nct07198841/), [IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer](https://onco.cc/trials/nct07377643/), [IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07402070/), [IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer](https://onco.cc/trials/nct07722494/), [IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small](https://onco.cc/trials/nct07122687/), [Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer](https://onco.cc/trials/nct05116462/), [ORIENT-11](https://onco.cc/trials/orient-11/), [ORIENT-16](https://onco.cc/trials/orient-16/), [ORIENT-32](https://onco.cc/trials/orient-32/), [Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer](https://onco.cc/trials/nct06121505/), [SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer](https://onco.cc/trials/nct07535632/), [Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](https://onco.cc/trials/nct06834672/)
- people: [Michael Yu (Yu De-Chao)](https://onco.cc/people/yu-michael/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)
- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)

---
JSON: https://onco.cc/api/v1/entities/innovent.json